Do not use for initial prostate cancer screening; preferred test is Prostate Specific Antigen, Screen (LAB111) in conjunction with digital rectal exam (DRE). May provide additional prostate cancer risk information for patients with mildly elevated total PSA and a negative DRE.
Includes Total PSA, Free PSA, and Percent FPSA
Orderable SIM Number(s)
PSA, TOTAL AND FREE (LAB171)
Synonyms
PSA, Free
Free Prostate Specific Antigen
Fractionated PSA
Free PSA
PSA Free/Total Ratio
PSA ratio
PSA Total and Free
Total PSA
LAB171
Hybrid PSA
Collect
Serum separator tube. Also acceptable: Mint (lithium heparin)
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum or plasma from cells ASAP or within 2 hours of collection. (Min: 0.5 mL)
Unacceptable Conditions
Grossly hemolyzed specimens.
Stability (from collection to initiation)
After separation from cells: Ambient: 8 hours; Refrigerated: 5 days; Frozen: 3 months
Reference Interval
By report
Results include: PSA-Free, PSA, PSA-Percent Free
Interpretive Data
In patients with total PSA concentrations of 4-10 ng/mL, the probability of finding prostate cancer on needle biopsy by age in years is:
Other factors may help determine the actual risk of prostate cancer in individual patients.
ARL uses the Roche Free PSA electrochemiluminescent immunoassay method in conjunction with the Roche Total PSA electrochemiluminescent immunoassay method to determine the free PSA percentage. Values obtained with different assay methods should not be used interchangeably. The free PSA percentage is an aid in distinguishing prostate cancer from benign prostatic conditions in individuals with a prostate age 50 years and older with a total PSA between 3 and 10 ng/mL and negative digital rectal examination findings. Prostatic biopsy is required for the diagnosis of cancer.”
Notes
The free percentage is calculated using the total and free PSA results.
CPT Codes
84153; 84154
Billable SIM Number(s)
3018415301 (CPT 84153)
3018415401 (CPT 84154)
LOINC
83112-3
10886-0
12841-3
Overview
Ordering Recommendations
Do not use for initial prostate cancer screening; preferred test is Prostate Specific Antigen, Screen (LAB111) in conjunction with digital rectal exam (DRE). May provide additional prostate cancer risk information for patients with mildly elevated total PSA and a negative DRE.
Includes Total PSA, Free PSA, and Percent FPSA
Orderable SIM Number(s)
PSA, TOTAL AND FREE (LAB171)
Synonyms
PSA, Free
Free Prostate Specific Antigen
Fractionated PSA
Free PSA
PSA Free/Total Ratio
PSA ratio
PSA Total and Free
Total PSA
LAB171
Hybrid PSA
Specimen
Collect
Serum separator tube. Also acceptable: Mint (lithium heparin)
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum or plasma from cells ASAP or within 2 hours of collection. (Min: 0.5 mL)
Unacceptable Conditions
Grossly hemolyzed specimens.
Stability (from collection to initiation)
After separation from cells: Ambient: 8 hours; Refrigerated: 5 days; Frozen: 3 months
Interpretive
Reference Interval
By report
Results include: PSA-Free, PSA, PSA-Percent Free
Interpretive Data
In patients with total PSA concentrations of 4-10 ng/mL, the probability of finding prostate cancer on needle biopsy by age in years is:
Other factors may help determine the actual risk of prostate cancer in individual patients.
ARL uses the Roche Free PSA electrochemiluminescent immunoassay method in conjunction with the Roche Total PSA electrochemiluminescent immunoassay method to determine the free PSA percentage. Values obtained with different assay methods should not be used interchangeably. The free PSA percentage is an aid in distinguishing prostate cancer from benign prostatic conditions in individuals with a prostate age 50 years and older with a total PSA between 3 and 10 ng/mL and negative digital rectal examination findings. Prostatic biopsy is required for the diagnosis of cancer.”
Notes
The free percentage is calculated using the total and free PSA results.
